Literature DB >> 20950339

N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers.

Helena Decker1, Sofia Jürgensen, Martin F Adrover, Jordano Brito-Moreira, Theresa R Bomfim, William L Klein, Alberto L Epstein, Fernanda G De Felice, Diana Jerusalinsky, Sergio T Ferreira.   

Abstract

Soluble amyloid-β peptide (Aβ) oligomers, known to accumulate in Alzheimer's disease brains, target excitatory post-synaptic terminals. This is thought to trigger synapse deterioration, a mechanism possibly underlying memory loss in early stage Alzheimer's disease. A major unknown is the identity of the receptor(s) targeted by oligomers at synapses. Because oligomers have been shown to interfere with N-methyl-d-aspartate receptor (NMDAR) function and trafficking, we hypothesized that NMDARs might be required for oligomer binding to synapses. An amplicon vector was used to knock-down NMDARs in mature hippocampal neurons in culture, yielding 90% reduction in dendritic NMDAR expression and blocking neuronal oxidative stress induced by Aβ oligomers, a pathological response that has been shown to be mediated by NMDARs. Remarkably, NMDAR knock-down abolished oligomer binding to dendrites, indicating that NMDARs are required for synaptic targeting of oligomers. Nevertheless, oligomers do not appear to bind directly to NMDARs as indicated by the fact that both oligomer-attacked and non-attacked neurons exhibit similar surface levels of NMDARs. Furthermore, pre-treatment of neurons with insulin down-regulates oligomer-binding sites in the absence of a parallel reduction in surface levels of NMDARs. Establishing that NMDARs are key components of the synaptic oligomer binding complex may illuminate the development of novel approaches to prevent synapse failure triggered by Aβ oligomers.
© 2010 The Authors. Journal of Neurochemistry © 2010 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20950339     DOI: 10.1111/j.1471-4159.2010.07058.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  65 in total

Review 1.  Synapses and Alzheimer's disease.

Authors:  Morgan Sheng; Bernardo L Sabatini; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-05-01       Impact factor: 10.005

2.  A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease.

Authors:  Sara Landgren; Malin von Otter; Mona Seibt Palmér; Caroline Zetterström; Staffan Nilsson; Ingmar Skoog; Deborah R Gustafson; Lennart Minthon; Anders Wallin; Niels Andreasen; Nenad Bogdanovic; Jan Marcusson; Kaj Blennow; Henrik Zetterberg; Petronella Kettunen
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

Review 3.  Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.

Authors:  Nicholas M Kanaan; Gustavo F Pigino; Scott T Brady; Orly Lazarov; Lester I Binder; Gerardo A Morfini
Journal:  Exp Neurol       Date:  2012-06-19       Impact factor: 5.330

Review 4.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 5.  Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease.

Authors:  Tae-In Kam; Youngdae Gwon; Yong-Keun Jung
Journal:  Cell Mol Life Sci       Date:  2014-08-24       Impact factor: 9.261

Review 6.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

Review 7.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Authors:  Sergio T Ferreira; William L Klein
Journal:  Neurobiol Learn Mem       Date:  2011-09-06       Impact factor: 2.877

Review 8.  Taming glutamate excitotoxicity: strategic pathway modulation for neuroprotection.

Authors:  Ming Jia; Steve A Noutong Njapo; Vaibhav Rastogi; Vishnumurthy Shushrutha Hedna
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 9.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 10.  Alzheimer's disease and insulin resistance: translating basic science into clinical applications.

Authors:  Fernanda G De Felice
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.